In patients with platinum-sensitive relapsed ovarian cancer harbouring BRCA1/2 mutation, final overall survival (OS) results from the phase 3 SOLO2/ENGOT-ov21 trial showed significant benefit for patients receiving maintenance treatment with olaparib over placebo.
Prof. Andrés Poveda (Hospital Quironsalud, Spain) presented the results, after approximately 5 years of follow-up . The trial enrolled patients with a *BRCA* mutation with relapsed high-grade serous ovarian cancer or endometrioid cancer. Patients had received at least 2 prior lines of platinum-based chemotherapy and were in a complete or partial response.
Participants were randomised to receive 300 mg olaparib twice daily (n=196) or placebo (n=99), and treatment continued until disease progression occurred, with a median follow-up of 65.7 months in the olaparib arm and 64.5 months in the placebo arm. The primary endpoint was ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Carfilzomib: no PFS benefit for multiple myeloma Next Article
Adjuvant pembrolizumab: durable RFS for Stage III melanoma »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.